This offers a plausible explanation for the disjuncture between our in vitro and in vivo T cell activation data, which has also been documented by Hu-Lieskovan and colleagues25, and further supports the complementarity of MEK inhibitors and agonist anti-CD40 Ab in tumor therapy. Here, MAP2K7 is linked to neoplasm.